LEASES

9 Months Ended

Sep. 30, 2025

The Company has operating leases that primarily relate to operating facilities in both the United States and Germany. The Company leases its operating facilities under operating lease arrangements with varying expiration dates through March 2037. As of September 30, 2025, the remaining lease term of the Company’s operating leases ranges from six to twelve years.

Supplemental statement of operations and cash flows related to the operating lease liability is as follows (excluding variable payments and expenses):

Supplemental balance sheet information related to operating leases is as follows:


	September 30,			December 31,
	2025			2024

	(amounts, in thousands)
Right-of-use asset	$	11,075		$	11,511
Lease liability - current portion	$	518		$	453
Lease liability - net of current portion		12,051			12,444
Total lease liability	$	12,569		$	12,897
Weighted average discount rate		9.8	%		9.8	%
Weighted average remaining lease term		11.4 years			11.7 years

Lease Expense

The components of lease expense were as follows:


	Three Months Ended September 30,
	2025		2024

	(amounts, in thousands)
Operating lease cost	$	440	$	409
Variable lease cost		207		156
Total lease cost	$	647	$	565


	Nine Months Ended September 30,
	2025		2024

	(amounts, in thousands)
Operating lease cost	$	1,288	$	1,297
Variable lease cost		356		360
Total lease cost	$	1,644	$	1,657

As of September 30, 2025, the maturities of the operating lease liability are as follows:


Remainder of 2025	$	431
2026		1,736
2027		1,777
2028		1,819
2029		1,863
Thereafter		13,550
Future operating lease payments		21,176
Imputed interest		(8,607)
Total operating lease liability	$	12,569

September 30,

(amounts, in thousands)

Cash paid in connection with the operating leases

Cytosorbents Corp 10-Q